Adaptimmune Therapeutics plc (NASDAQ:ADAP) Short Interest Update

Adaptimmune Therapeutics plc (NASDAQ:ADAP) was the target of a large increase in short interest in March. As of March 15th, there was short interest totalling 3,110,000 shares, an increase of 11.1% from the February 29th total of 2,800,000 shares. Based on an average daily volume of 1,850,000 shares, the short-interest ratio is presently 1.7 days.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on Adaptimmune Therapeutics in a report on Friday, December 29th. They issued a “hold” rating for the company.

Adaptimmune Therapeutics Stock Performance

Shares of NASDAQ:ADAP opened at $1.47 on Tuesday. The business’s 50 day simple moving average is $1.33 and its two-hundred day simple moving average is $0.88. The firm has a market cap of $1.46 billion, a P/E ratio of -2.67 and a beta of 2.39. Adaptimmune Therapeutics has a 52-week low of $0.42 and a 52-week high of $2.05.

Adaptimmune Therapeutics (NASDAQ:ADAP) last issued its quarterly earnings data on Wednesday, March 6th. The biotechnology company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.12). The company had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $4.80 million. Adaptimmune Therapeutics had a negative return on equity of 155.39% and a negative net margin of 188.90%. On average, equities analysts forecast that Adaptimmune Therapeutics will post -0.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Adaptimmune Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Harbor Capital Advisors Inc. boosted its stake in Adaptimmune Therapeutics by 9.9% during the fourth quarter. Harbor Capital Advisors Inc. now owns 147,732 shares of the biotechnology company’s stock valued at $117,000 after buying an additional 13,317 shares during the period. State Street Corp raised its position in Adaptimmune Therapeutics by 5.9% during the first quarter. State Street Corp now owns 284,741 shares of the biotechnology company’s stock valued at $310,000 after purchasing an additional 15,943 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in shares of Adaptimmune Therapeutics by 56.4% in the second quarter. Goldman Sachs Group Inc. now owns 48,077 shares of the biotechnology company’s stock worth $44,000 after buying an additional 17,332 shares during the period. Key Client Fiduciary Advisors LLC lifted its stake in shares of Adaptimmune Therapeutics by 6.4% in the 4th quarter. Key Client Fiduciary Advisors LLC now owns 336,620 shares of the biotechnology company’s stock valued at $267,000 after acquiring an additional 20,295 shares during the last quarter. Finally, UBS Group AG lifted its stake in shares of Adaptimmune Therapeutics by 1,090.8% in the 4th quarter. UBS Group AG now owns 23,625 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 21,641 shares during the last quarter. 31.37% of the stock is owned by institutional investors.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.